Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance.

AIMS Systemic sclerosis (SSc) may induce cardiac fibrosis and systo-diastolic dysfunction. Cardiovascular magnetic resonance (CMR) can detect replacement myocardial fibrosis with late gadolinium enhancement (LGE) and interstitial myocardial fibrosis with T1 mapping techniques. The aim of the study was to detect subclinical cardiac involvement with CMR in paucisymptomatic SSc patients with no previous history of myocardial disease, comparing it with skeletal muscle remodelling. METHODS AND RESULTS Thirty consecutive SSc patients (mean age: 51 ± 12 years, all women) and 10 healthy controls (mean age: 48 ± 15 years, all women) underwent clinical, biohumoral assessment, and CMR. Extracellular volume fraction (ECV) was calculated from pre- and post-contrast T1 values in the myocardium and skeletal muscle. Seventeen patients (57%) were asymptomatic, 13 (43%) paucisymptomatic (effort dyspnoea). All patients had normal biventricular volumes and systolic function, while LGE was present in seven patients (23%). Myocardial ECV was significantly increased in patients with SSc (30 ± 4%) than controls (28 ± 4%, P = 0.03), as was skeletal muscle ECV (23 ± 6% vs. 18 ± 4%, P < 0.01). Myocardial ECV did not differ between patients with and without LGE (P = NS) and showed no significant correlations with clinical data, biventricular volumes, systolic, or diastolic function. Overall, myocardial ECV showed a significant correlation with skeletal muscle ECV (R = 0.58, P < 0.001). CONCLUSION SSc is associated not only with myocardial replacement fibrosis, as detected by LGE, but also with interstitial remodelling of the myocardium and skeletal muscles, as detected by an increased ECV also in patients with normal biventricular function, with potential diagnostic, prognostic, and therapeutic clinical implications.

[1]  Richard B. Thompson,et al.  Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. , 2014, Radiology.

[2]  P. Matthews,et al.  Subclinical myocardial inflammation and diffuse fibrosis are common in systemic sclerosis – a clinical study using myocardial T1-mapping and extracellular volume quantification , 2014, Journal of Cardiovascular Magnetic Resonance.

[3]  P. Croisille,et al.  Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. , 2014, Radiology.

[4]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[5]  M. Robson,et al.  Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement , 2013, Journal of Cardiovascular Magnetic Resonance.

[6]  Stefan Neubauer,et al.  T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. , 2013, JACC. Cardiovascular imaging.

[7]  Chia-Ying Liu,et al.  Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). , 2013, Journal of the American College of Cardiology.

[8]  M. Conforti,et al.  Early detection of myocardial and pulmonary oedema with MRI in an asymptomatic systemic sclerosis patient: successful recovery with pulse steroid. , 2013, Rheumatology.

[9]  M. Robson,et al.  T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. , 2013, JACC. Cardiovascular imaging.

[10]  C. Masciocchi,et al.  Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). , 2013, European journal of radiology.

[11]  Andrew S Flett,et al.  Human non-contrast T1 values and correlation with histology in diffuse fibrosis , 2013, Heart.

[12]  P. Siotto,et al.  Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests , 2013, Arthritis Research & Therapy.

[13]  C. Hardy,et al.  Modified cine inversion recovery pulse sequence for the quantification of myocardial T1 and gadolinium partition coefficient , 2013, Journal of magnetic resonance imaging : JMRI.

[14]  M. Emdin,et al.  CMR-verified interstitial myocardial fibrosis as a marker of subclinical cardiac involvement in LMNA mutation carriers. , 2013, JACC. Cardiovascular imaging.

[15]  Andrew S Flett,et al.  Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR , 2012, Journal of Cardiovascular Magnetic Resonance.

[16]  J. Reiber,et al.  Myocardial perfusion-fibrosis pattern in systemic sclerosis assessed by cardiac magnetic resonance. , 2012, International journal of cardiology.

[17]  Andrew S Flett,et al.  Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease , 2012, Heart.

[18]  M. Robson,et al.  Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[19]  M. Mayes,et al.  Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers , 2012, Current opinion in rheumatology.

[20]  D. Bluemke,et al.  Myocardial T1 mapping with MRI: Comparison of look‐locker and MOLLI sequences , 2011, Journal of magnetic resonance imaging : JMRI.

[21]  Daniel C. Lee,et al.  Systemic sclerosis and the heart: current diagnosis and management , 2011, Current opinion in rheumatology.

[22]  E. Paiva,et al.  Envolvimento das musculaturas esquelética e cardíaca na esclerose sistêmica , 2011 .

[23]  L. Czirják,et al.  Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. , 2011, Rheumatology.

[24]  E. Paiva,et al.  Skeletal and cardiac muscles involvement in systemic sclerosis. , 2011, Revista brasileira de reumatologia.

[25]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[26]  M. Hayward,et al.  Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.

[27]  D. Farge,et al.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[28]  O. Vignaux,et al.  Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. , 2010, Archives of cardiovascular diseases.

[29]  K. Fontaine,et al.  Cardiac Magnetic Resonance Imaging with Pharmacological Stress Perfusion and Delayed Enhancement in Asymptomatic Patients with Systemic Sclerosis , 2008, The Journal of Rheumatology.

[30]  N. Lamblin,et al.  Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients , 2008, Annals of the rheumatic diseases.

[31]  J. Barkhausen,et al.  Detection of Myocardial Fibrosis in Systemic Sclerosis by Contrast-Enhanced Magnetic Resonance Imaging , 2008, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[32]  P. Hunold,et al.  2029 Systemic sclerosis: detection of myocardial fibrosis by contrast-enhanced MRI , 2008 .

[33]  N. Kelekis,et al.  Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. , 2007, Arthritis and rheumatism.

[34]  L. Mouthon,et al.  Systemic Sclerosis‐Associated Myopathy , 2007, Annals of the New York Academy of Sciences.

[35]  R. Abbate,et al.  Angiotensin‐Converting Enzyme in Systemic Sclerosis , 2006 .

[36]  N. Kelekis,et al.  Magnetic resonance imaging for the detection of myocardial fibrosis in scleroderma. , 2006, The New England journal of medicine.

[37]  David M Higgins,et al.  Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution--reproducibility study. , 2006, Radiology.

[38]  R. Abbate,et al.  Angiotensin-converting enzyme in systemic sclerosis: from endothelial injury to a genetic polymorphism. , 2006, Annals of the New York Academy of Sciences.

[39]  D. Pennell,et al.  Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[40]  M. Emdin,et al.  Heart involvement and systemic sclerosis , 2005, Lupus.

[41]  Olga Bondarenko,et al.  Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. , 2005, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[42]  J. Ioannidis,et al.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data. , 2005, The American journal of medicine.

[43]  E. Bonfá,et al.  Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. , 2003, Journal of cardiac failure.

[44]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[45]  D. Pennell,et al.  Systemic sclerosis involving the heart , 2001, Heart.

[46]  N. Olsen,et al.  Muscle abnormalities in scleroderma. , 1996, Rheumatic diseases clinics of North America.

[47]  T. Medsger,et al.  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. , 1993, American heart journal.

[48]  M. Duncan,et al.  Scleroderma: A Model for Fibrosis , 1983 .

[49]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[50]  G. Hutchins,et al.  Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.

[51]  T. N. James,et al.  De Subitaneis Mortibus: VIII. Coronary Arteries and Conduction System in Scleroderma Heart Disease , 1974, Circulation.

[52]  T. K. Marshall,et al.  De Subitaneis Mortibus: V. Occluded A‐V Node Artery , 1974, Circulation.